2024 ASCO-GU非透明细胞肾细胞癌研究进展  

2024 ASCO-GU progress in non-clear cell renal cell carcinoma

作　　者：孔文[1] 刘振华[2] 张进[1] 曾浩[2] Kong Wen;Liu Zhenhua;Zhang Jin;Zeng Hao(Department of Urology,Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]上海交通大学医学院附属仁济医院泌尿外科,上海200127 [2]四川大学华西医院泌尿外科,成都610041

出　　处：《中华泌尿外科杂志》2024年第4期251-253,共3页Chinese Journal of Urology

摘　　要：2024 ASCO-GU年会公布了KEYNOTE-B61研究更新的随访结果,再次显示出靶免联合治疗在晚期非透明细胞肾细胞癌中获得满意的疗效和安全性;乳头状癌和嫌色细胞癌对免疫治疗的应答差异与其肿瘤微环境特征显著相关;与不同伴侣基因的融合对TFE3重排肾癌的治疗有决定性影响。One of the remarkable progresses regarding non-clear cell renal cell carcinoma in the 2024 ASCO-CU symposium was the survival update of KEYNOTE-B61 study,in which tyrosine kinase inhibitor plus immunotherapy(TKI-IO)combination maintained satisfactory efficacy and safety.The distinct response to immunotherapy between papillary versus chromophobe renal cell carcinoma was demonstrated closely correlated with tumor microenvironment.The fusion partner of TFE-rearranged renal cell carcinoma directly determined the tumor biological behavior and therapeutic response.

关 键 词：靶免联合 肿瘤微环境 伴侣基因 

分 类 号：R737.11[医药卫生—肿瘤]